Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy

European Heart Journal

Volumn 32, Issue 20, 2011, Pages 2507-2515

  Tardif, Jean Claude ^a   Omeara, Eileen ^a   Komajda, Michel ^b   Böhm, Michael ^c   Borer, Jeffrey S ^d   Ford, Ian ^e   Tavazzi, Luigi ^f   Swedberg, Karl ^g  

^a MONTREAL HEART INSTITUTE   (Canada)

^b SORBONNE UNIVERSITÉ   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MARIA CECILIA HOSPITAL   (Italy)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Heart failure; Heart rate; Ivabradine; Systolic dysfunction; Ventricular remodelling

Indexed keywords

IVABRADINE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SYSTOLIC DYSFUNCTION;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BENZAZEPINES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80054742115     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr311     Document Type: Article

References (23)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. On Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582. (Pubitemid 30167013)
2. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75. (Pubitemid 24026473)
3. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-3744. (Pubitemid 43739514)
4. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C; REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009;120:1858-1865.
5. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J Am Coll Cardiol 2010;56:392-406.
6. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled trial. Lancet 2010;376:875-885.
7. Erratum in Lancet 2010;376:1988.
8. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure : The Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber of Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463. (Pubitemid 41821197)
10. Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P, Parrinello G, Robertson M, Steg PG, Tendera M, Ford I, Fox K, Ferrari R; BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 2011;146:408-414.
11. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679. (Pubitemid 38451726)
12. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E, Mugelli A, Ferrari R. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 2010;300: H366-H373.
13. Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 2007;293:H590-H598. (Pubitemid 47105120)
14. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 2009;296: H435-H441.
15. Vercauteren M, Favre J, Mulder P, Mahlberg-Gaudin F, Thuillez C, Richard V. Protection of endothelial function by long-term heart rate reduction induced by ivabradine in a rat model of chronic heart failure. Eur Heart J 2007;28(suppl):48. P468.
16. Gupta RC, Wang M, Ilsar I, Sabbah MS, Dye K, Cavanagh A, Sabbah HN. Heart rate reduction with ivabradine improves sarcoplasmic reticulum calcium cycling in left ventricular myocardium of dogs with moderate heart failure. J Am Coll Cardiol 2011;57:E323.
17. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy. Circulation 2004;109:201-206. (Pubitemid 38114140)
18. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166:659-666.
19. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A. Prognostic value of bisoprolol-induced hemodynamic effects in Heart Failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997;96:2197-2205. (Pubitemid 27425823)
20. van de Ven LL, Van Veldhuisen DJ, Goulder M, Zilahi Z, Meyer WR, Willenheimer R. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. Int J Cardiol 2010;144:59-63.
21. Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, Furuno T, Takata J, Doi YL. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011;107:1065-1070.
22. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Hermann-Lingen C, Gelbrich G, Dietz R. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: The CIBIS-ELD trial. Eur J Heart Fail 2011;13:670-680.
23. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94: 2807-2816. (Pubitemid 26411745)